ERBB2 and inflammatory breast carcinoma: However, Jiao et al. observed a limited effectiveness of neoadjuvant trastuzumab and pertuzumab therapy for 2+ HER2-IHC/ISH positive IBC, compared to 3+ HER2-IHC cases and attributed this finding to subtype heterogeneity [27,32].